Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have received a consensus rating of “Moderate Buy” from the twenty-three analysts that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $131.22.

Several research firms recently issued reports on SRPT. The Goldman Sachs Group cut their price target on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday. Needham & Company LLC reduced their price target on Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday. Wells Fargo & Company dropped their price objective on Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday. Cantor Fitzgerald reduced their target price on Sarepta Therapeutics from $163.00 to $81.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, HC Wainwright lowered their price target on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a “neutral” rating on the stock in a research note on Wednesday.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. CenterBook Partners LP purchased a new stake in Sarepta Therapeutics in the 1st quarter valued at about $281,000. Charles Schwab Investment Management Inc. grew its holdings in Sarepta Therapeutics by 3.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 646,291 shares of the biotechnology company’s stock valued at $41,246,000 after purchasing an additional 22,542 shares during the period. Raiffeisen Bank International AG increased its position in Sarepta Therapeutics by 1,092.2% during the first quarter. Raiffeisen Bank International AG now owns 17,465 shares of the biotechnology company’s stock worth $1,220,000 after purchasing an additional 16,000 shares during the last quarter. Blueshift Asset Management LLC purchased a new position in Sarepta Therapeutics during the first quarter worth approximately $488,000. Finally, Sound View Wealth Advisors Group LLC grew its stake in shares of Sarepta Therapeutics by 18.8% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 4,863 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 771 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 0.7 %

Shares of NASDAQ SRPT opened at $36.27 on Tuesday. The stock has a market cap of $3.56 billion, a PE ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics has a 52-week low of $35.46 and a 52-week high of $173.25. The business has a 50-day moving average price of $66.84 and a 200 day moving average price of $100.66. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. During the same period in the previous year, the business posted $0.73 earnings per share. The company’s revenue for the quarter was up 80.2% on a year-over-year basis. Equities research analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.